Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
暂无分享,去创建一个
G. Stone | A. Kirtane | G. Dangas | R. Mehran | S. Bansilal | S. Brener | B. Redfors | O. Ben‐Yehuda | Cristiano F Souza | Shmuel Chen | Yiran Zhang | Xin Huang | F. Feite | O. Ben-Yehuda
[1] P. Jüni,et al. Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation , 2017, European heart journal.
[2] S. Windecker,et al. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial , 2016, British Medical Journal.
[3] P. Jüni,et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[4] G. Stone,et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. , 2015, JAMA.
[5] S. Pocock,et al. Bivalirudin started during emergency transport for primary PCI. , 2013, The New England journal of medicine.
[6] Jörg Hausleiter,et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.
[7] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[8] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[9] K. Eagle,et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.
[10] A. Kastrati,et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.
[11] A. Defranco,et al. Prognostic Implication of Anemia on In-Hospital Outcomes After Percutaneous Coronary Intervention , 2004, Circulation.
[12] E. Braunwald,et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.
[13] A. Go,et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. , 2001, Journal of the American College of Cardiology.
[14] H. White,et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban , 1999, The Lancet.
[15] F. Harrell,et al. Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia , 1996 .